The impact of RAS mutation on the treatment strategy of colorectal cancer

Authors

  • Edvina Elena Pirvu
  • Emilia Severin
  • Irina Niţă
  • Ștefania Andreea Toma

DOI:

https://doi.org/10.15386/mpr-2408

Keywords:

colorectal cancer, KRAS, adjuvant, metastatic

Abstract

Kirsten rat sarcoma (KRAS) is the most frequently mutated oncogene in colorectal cancer, being present in 30% of patients with localized disease and in almost half of the patients that develop metastatic disease. While the development of chemotherapy doublets and targeted therapy have improved survival in recent years, KRAS mutation still has a controversial role regarding its prognostic and predictive value both in the adjuvant and in the metastatic setting. The impact of KRAS mutation on treatment strategy remains to be better defined. The development of new KRAS inhibitors promising new treatment options is on the horizon.

Downloads

Published

2023-01-18

How to Cite

1.
Pirvu EE, Severin E, Niţă I, Toma Ștefania A. The impact of RAS mutation on the treatment strategy of colorectal cancer. Med Pharm Rep [Internet]. 2023 Jan. 18 [cited 2025 Oct. 26];96(1):5-15. Available from: https://medpharmareports.com/index.php/mpr/article/view/2408

Issue

Vol. 96 No. 1 (2023)

Section

Reviews

License

The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.

 Creative Commons License
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.